A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects
Status:
Completed
Trial end date:
2016-12-15
Target enrollment:
Participant gender:
Summary
MOD-6031 is a long-acting reversibly PEGylated oxyntomodulin (OXM) therapeutic. The active
moiety is a gastrointestinal neuropeptide with a sequence identical to endogenous human OXM
and is an agonist for both glucagon-like peptide-1 (GLP1) and glucagon (GCG) receptors. The
peptide is a natural appetite suppressant, secreted by L-cells in the digestive system
following food intake leading to a decrease in gastric emptying, satiety after crossing the
blood-brain barrier, and regulation of insulin and glucose levels. Thus, MOD-6031 is being
developed as a treatment for high risk subjects (obese) to increase weight loss, reduce food
intake and increase glycemic control.